Press coverage about Dimension Therapeutics (NASDAQ:DMTX) has trended positive on Saturday, according to Accern. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dimension Therapeutics earned a media sentiment score of 0.29 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 44.3659541865251 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Several research firms recently weighed in on DMTX. Citigroup cut shares of Dimension Therapeutics from a “neutral” rating to a “sell” rating and raised their target price for the company from $3.41 to $5.50 in a research note on Tuesday, September 19th. Wells Fargo & Co cut shares of Dimension Therapeutics from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $9.00 to $6.00 in a research note on Tuesday, October 3rd. Chardan Capital reissued a “buy” rating on shares of Dimension Therapeutics in a research note on Friday, December 22nd. Finally, ValuEngine raised shares of Dimension Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 30th. Two analysts have rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. Dimension Therapeutics has an average rating of “Hold” and an average target price of $5.08.
Dimension Therapeutics (NASDAQ:DMTX) remained flat at $$5.95 during trading hours on Friday. Dimension Therapeutics has a 1-year low of $1.05 and a 1-year high of $6.10. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.01 and a quick ratio of 3.33. The firm has a market capitalization of $149.06 and a P/E ratio of -2.67.
Dimension Therapeutics (NASDAQ:DMTX) last released its earnings results on Monday, November 6th. The biotechnology company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.20). Dimension Therapeutics had a negative net margin of 378.28% and a negative return on equity of 240.95%. The firm had revenue of $4.48 million during the quarter. sell-side analysts anticipate that Dimension Therapeutics will post -1.99 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Dimension Therapeutics (DMTX) Getting Favorable News Coverage, Analysis Shows” was first posted by Stock Observer and is owned by of Stock Observer. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.thestockobserver.com/2018/01/13/dimension-therapeutics-dmtx-getting-favorable-news-coverage-analysis-shows.html.
Dimension Therapeutics Company Profile
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
Receive News & Ratings for Dimension Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.